Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26263547 | 0.86 | ALDH1A1 (0.56) | TDP1SMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL23589539 | 0.85 | ALDH1A1 (0.44) | TDP1TSHRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL5478946 | 0.84 | ALDH1A1 (0.42) | TDP1TSHRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL23908460 | 0.81 | ALDH1A1 (0.41) | TDP1TSHRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL8300172 | 0.78 | TDP1 (0.60) | TDP1TSHRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL29229957 | 0.77 | TDP1 (0.69) | TDP1TSHRSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5501219 | 0.76 | TDP1 (0.42) | TDP1TSHRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL26263634 | 0.75 | HTR1A (0.51) | TDP1TSHRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL29391066 | 0.75 | TDP1 (0.69) | TDP1TSHRSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL16501188 | 0.75 | MAPT (0.42) | TSHRALDH1A1KMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077737-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20110294778-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294778-A1 | HEPATITIS C INHIBITOR COMPOUNDS | ABCC1, CTRC, HAVCR2 | TDP1 3287/4885TSHR 3288/4885SMN1; SMN2 4586/4885 |
| US-20120077737-A1 | HEPATITIS C INHIBITOR COMPOUNDS | CTSC, HCCS, CTSZ | TDP1 4417/4885TSHR 4427/4885SMN1; SMN2 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.